Monitoring intravesical bacillus Calmette-Guerin treatment of bladder carcinoma with flow cytometry Academic Article uri icon


MeSH Major

  • BCG Vaccine
  • Carcinoma in Situ
  • Monitoring, Physiologic
  • Urinary Bladder Neoplasms


  • Flow cytometry of bladder irrigation specimens was studied in 22 patients with low stage bladder carcinoma who were treated by transurethral resection of visible tumor followed in 3 to 5 weeks by a course of intravesical bacillus Calmette-Guerin. The most informative examinations were just before the first bacillus Calmette-Guerin treatment, 6 weeks after completing a 6-week course of treatment (3 months) and at 9 months. Of the patients 10 had recurrent tumors after therapy; recurrence was anticipated correctly by flow cytometry at the 12-week followup examination in 6 of the 10 patients and suspected in another. Of 12 patients who remained clinically free of disease for a minimum of 15 months after bacillus Calmette-Guerin therapy flow cytometry identified correctly 7 at 12 weeks, while 1 had a partial response and the remaining 4 reverted to a negative status at 9 months. Of interest, only 4 of the 22 patients were free of disease by flow cytometry at the start of bacillus Calmette-Guerin treatment despite attempted ablation of the tumor by transurethral resection, suggesting that intravesical administration of bacillus Calmette-Guerin destroys existing carcinoma in situ in some cases.

publication date

  • October 2, 1985



  • Academic Article



  • eng

PubMed ID

  • 3989917

Additional Document Info

start page

  • 786

end page

  • 8


  • 133


  • 5